Centaurus Financial’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-4,655
Closed -$112K 868
2022
Q3
$112K Buy
+4,655
New +$120K 0.01% 778

Other funds holding FTXH

Centaurus Financial's FTXH Position: Q4 2022 in Review

Centaurus Financial sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q4 2022, closing a stake of 4,655 shares — an estimated $112K sold.

Centaurus Financial first reported a position in FTXH in Q3 2022 and held it in 1 quarter. The position peaked at $112K in Q3 2022. 34 funds tracked by Wall St. Rank hold FTXH as of Q4 2022.

  • Centaurus Financial reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q4 2022 after selling out during the quarter.
  • Centaurus Financial sold 4,655 First Trust Nasdaq Pharmaceuticals ETF shares in Q4 2022, an estimated $112K.
  • Centaurus Financial first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2022 and held it in 1 quarter.
  • Centaurus Financial's First Trust Nasdaq Pharmaceuticals ETF position peaked at $112K in Q3 2022.
  • 34 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q4 2022.

Based on Centaurus Financial's 13F filing for Q4 2022, filed 13 Feb 2023.